Mr. Paul Sweetman:

I thank the Chair. On the clinical trials aspect, this is something that with the right policy levers we can encourage more of in Ireland. There is a significant opportunity if we play our cards right, particularly in the research and development space if we can make the right tweaks to the research and development tax credit. Mr. O'Callaghan is our expert in that regard, so I can hand over to him to address that point. There is an opportunity there.

We would certainly like to work with the committee on what needs to be done in that space.